Universal Cells

Universal Cells develops engineered allogeneic stem cells with proprietary nuclease-free gene editing technology to create "universal donor" pluripotent stem cells that can be differentiated into various therapeutic cell types while avoiding immune rejection. Their approach focuses on precise HLA engineering using rAAV vectors, aiming for off-the-shelf cell therapy products suitable for any patient without the need for immunosuppression or matching. The company was acquired by Astellas Pharma in February 2018 but continues operations as an active subsidiary focused on advancing its platform toward clinical applications in regenerative medicine and transplantation.